Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux versus nadroparin calcium for venous thromboembolism prevention after hip or knee arthroplasty
ChiCTR2100042205Phase 4Recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Jan 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux and nadroparin in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Color Doppler ultrasound of lower extremity vessels at week 12. Started Jan 2021; status: recruiting.
02
Drugs
fondaparinuxnadroparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on ChiCTR2100042205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042205.